TAURIN INFLUENCE ON CLINICAL COURSE OF STAbLE ANGINA IN POSTINFARCTION CARDIOSCLEROSIS PATIENTS
https://doi.org/10.15829/1560-4071-2018-4-82-88
Abstract
Aim. Study of efficacy and safety of taurin in management of stable angina patients with postinfarction cardiosclerosis.
Material and methods. Totally, 95 postinfarction cardiosclerosis patients included, with stable angina of II and III functional class. The patients that were included, had refused revascularization. To the main group, 48 were included with added taurin (Dibicor, “PIK-Pharma”, Russia, 750 mg daily), and to comparison group — 47 patients that were taking standard treatment and placebo. Treatment duration 3 months.
Results. Clinical efficacy of taurin in postinfarction cardiosclerosis and stable angina is confirmed by significant improvement of the following parameters: subjective state (decreased fatigue, less complaints on palpitation, less severity of dyspnea and rarer angina attacks), of the life quality parameters by Seattle questionnaire; echocardiographic parameters, normalized cardiac rhythm. Postive changes achieved on the basis therapy with taurin, remained for 3 months after drug discontinuation.
Conclusion. Positive influence of taurin on clinical and instrumental parameters of patients make it to recommend its prescription for stable angina treatment in postinfarction cardiosclerosis patients.
About the Authors
I. S. Vasilieva
I. M. Sechenov First Moscow State Medical University of the Ministry of Health.
Russian Federation
Moscow.
Russian Federation
Moscow.
V. V. Rezvan
I. M. Sechenov First Moscow State Medical University of the Ministry of Health.
Russian Federation
Moscow.
Russian Federation
Moscow.
References
1. Van de Werf F, Crea F. The year in cardiology 2014: acute coronary syndromes. Eur. Heart J. 2015; 36: 342-6. DOI: 10.1093/eurheartj/ehu488. Epub 2015 Jan 2.
2. Nayyar S, Wilson L, Ganesan A, et al. Electrophysiologic features of protected channels in late postinfarction patients with and without spontaneous ventricular tachycardia. J. Interv. Card Electrophysiol. 2017; Dec 13. DOI: 10.1007/s10840-017-0299-6. [Epub ahead of print].
3. Cacciapuoti F, Tirelli P, Cacciapuoti F. Left Ventricular Postinfarction Pseudoaneurysm: Diagnostic Advantages of Three-Dimensional Echocardiography. J Cardiovasc Echogr. 2017; 27 (2): 74-6. DOI: 10.4103/jcecho.jcecho_49_16.
4. Allo SN, Bagby L, Schaffer SW. Taurine depletion, a novel mechanism for cardioprotection from regional ischemia. Am. J. Physiol. 1997; 273: 1956-61.
5. D’yakova NA, Puzyreva IN, Ogaj MA, et al. Development of dosage forms with taurine. Bulletin of Voronezh State University. Series: Chemistry. Biology. Pharmacy. 2016; 1: P. 140-6. (In Russ.) Дьякова Н. А., Пузырева И. Н., Огай М. А. и др. Разработка лекарственных форм с таурином. Вестник Воронежского государственного университета. Серия: Химия. Биология. Фармация. 2016; 1: 140-6.
6. Doskina EV. What is taurine and “with what it is eaten”? Questions of dietetics. 2015; 5 (1): 58-61. (In Russ.) Доскина Е. В. Что такое таурин и “с чем его едят”? Вопросы диетологии. 2015; 5 (1): 58-61.
7. Nechaeva GI, Druk IV, Ryapolova EA. Efficacy and tolerability of taurine in patients with type 2 diabetes mellitus and left ventricular diastolic dysfunction. Polyclinic. 2015; 1: 58-62. (In Russ.) Нечаева Г. И., Друк И. В., Ряполова Е. А. Эффективность и переносимость таурина у пациентов с сахарным диабетом 2-го типа и диастолической дисфункцией левого желудочка. Поликлиника. 2015; 1: 58-62.
8. Schaffer SW, Shimada-Takaura K, Jong CJ, et al. Impaired energy metabolism of the taurinedeficient heart. Amino Acids. 2016; 48 (2): 549-58. DOI: 10.1007/s00726015-2110-2.
9. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995; 25 (2): 333-41.
10. Stacenko ME, Turkina SV, Shilina NN, Vinnikova AA. Endothelioprotective properties of taurine in patients with chronic heart failure and type 2 diabetes mellitus. Cardiovascular Therapy and Prevention. 2016; 15 (2): 38-44. (In Russ.) Стаценко М. Е., Туркина С. В., Шилина Н. Н., Винникова А. А. Эндотелиопротекторные свойства таурина у больных с хронической сердечной недостаточностью и сахарным диабетом 2 типа. Кардиоваскулярная терапия и профилактика. 2016; 15 (2): 38-44. DOI: 10.15829/1728-8800-2016-2-38-44.
11. Averin E. Use of taurine during rehabilitation after cardiac surgery. Adv. Exp. Med. Biol. 2015; 803: 637-649. DOI: 10.1007/978-3-319-15126-7_51.
Review
For citations:
Vasilieva I.S., Rezvan V.V. TAURIN INFLUENCE ON CLINICAL COURSE OF STAbLE ANGINA IN POSTINFARCTION CARDIOSCLEROSIS PATIENTS. Russian Journal of Cardiology. 2018;(4):82-88. (In Russ.) https://doi.org/10.15829/1560-4071-2018-4-82-88
Views:
1352
Email this article 